What is this study and why is it being done?
PrEP (HIV Pre-exposure Prophylaxis) is a medicine for HIV negative people. It can reduce the risk of catching HIV when taken as instructed. PrEP is made up of two drugs, Tenofovir and Emtricitabine. Both drugs have been widely used for many years to treat HIV. The drug has also been used by several thousands of HIV negative people to reduce the risk of HIV.
PrEP is available in some countries. To plan a PrEP programme in England, NHS England and local councils need to know how many people need it, how many will want to take it and for how long. This research is being conducting to find this out.
Many of the iCaSH clinics will be participating in this trial and we expect clinics to be opening to recruitment in the coming weeks. Please refer to www.prepimpacttrial.org.uk for the most up to date information on eligibility criteria, what participation involves, and the status of participating clinics.